180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, and its board of directors has initiated a process to evaluate potential strategic alternatives. The goal of the process is to identify ways to unlock and maximize shareholder value. According to the announcement, company officials are working with financial and legal advisors as they consider a full range of strategic, operational and financial options. The announcement noted that there is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome, and the company has not established a timeline for completion of the review process. Company officials don’t anticipate making any additional comments regarding the process unless or until board members approve a definitive course of action or determine that additional comments are appropriate.
To view the full press release, visit https://ibn.fm/DPWVj
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF, or tumor necrosis factor. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN